Wellell Biotech Announces 2025 Q4 Earnings: EPS of NT$2.96
NQ Score
57/100
N1 Content Completeness
4
AI Summary (NQ-processed)
Wellell Biotech Co., Ltd. (stock code 1783) reported its financial results for the fourth quarter of 2025. The company posted an earnings per share (EPS) of NT$2.96 for the quarter. Revenue reached NT$812 million, with a net profit after tax of NT$265 million. Wellell Biotech operates in the biotechnology and medical industry, focusing on collagen and hyaluronic acid.
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What was Wellell Biotech's revenue in Q4 2025?
- A: Wellell Biotech's operating revenue for Q4 2025 was NT$812 million.
- Q: What was Wellell Biotech's net profit in Q4 2025?
- A: The net profit after tax for Wellell Biotech in Q4 2025 was NT$265 million.
- Q: What is Wellell Biotech's stock code?
- A: Wellell Biotech's stock code is 1783.